Focus Partners Wealth
CORT icon

Focus Partners Wealth’s Corcept Therapeutics CORT Stock Holding History

Focus Partners Wealth’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.58M Sell
18,137
-14,602
-45% -$882K ﹤0.01% 1440
2026
Q1 		$1.32M Sell
32,739
-12,539
-28% -$469K ﹤0.01% 1491
2025
Q4 		$1.58M Buy
45,278
+455
+1% +$35.7K ﹤0.01% 1433
2025
Q3 		$3.73M Buy
44,823
+11,317
+34% +$819K 0.01% 837
2025
Q2 		$2.46M Buy
33,506
+263
+0.8% +$19.1K 0.01% 852
2025
Q1 		$3.8M Buy
33,243
+170
+0.5% +$10.3K 0.01% 703
2024
Q4 		$1.67M Buy
33,073
+675
+2% +$35.4K ﹤0.01% 893
2024
Q3 		$1.5M Buy
+32,398
New +$1.15M ﹤0.01% 840

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Focus Partners Wealth's CORT Position: Q2 2026 in Review

Focus Partners Wealth reduced its Corcept Therapeutics (CORT) stake by 45% in Q2 2026, selling an estimated $882K and leaving 18,137 shares worth $1.58M. The position accounts for ﹤0.01% of the portfolio, ranked #1440.

Focus Partners Wealth first reported a position in CORT in Q3 2024 and has held it in 8 quarters since. The position peaked at $3.8M in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Focus Partners Wealth held 18,137 shares of Corcept Therapeutics worth $1.58M as of Q2 2026.
  • Focus Partners Wealth sold 14,602 Corcept Therapeutics shares in Q2 2026, an estimated $882K.
  • Corcept Therapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #1440 holding.
  • Focus Partners Wealth first reported a position in Corcept Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Focus Partners Wealth's Corcept Therapeutics position peaked at $3.8M in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.